Ginkgo Bioworks: Unproven Transition But 2025 Is Looking Better
Analysis of Ginkgo Bioworks' Q3 results and business model, with a focus on growth, customer acquisition and cash flow ...
Struggling Ginkgo Bioworks says it will step away from soon-to-open Seaport building
One of the few bright spots in Boston’s life-science lab space market this year has dimmed.
Ginkgo Bioworks Holdings: Hold Rating Amidst Revenue Growth and Restructuring Efforts
In a report released yesterday, Tejas Savant from Morgan Stanley maintained a Hold rating on Ginkgo Bioworks Holdings (DNA – Research Report), ...
Ginkgo Bioworks: Not Enough Progress
Ginkgo Bioworks reported mixed Q3, with a $45M one-time revenue boost masking underlying revenue growth issues. Read why I ...
Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the ...
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 12, 2024 Megan LeDuc: Good evening. I’m Megan LeDuc, Manager of Investor Relations ...
Banker & Tradesman4d
Ginkgo Bioworks Drops Move to New Seaport Development
Ginkgo Bioworks is offering its newly-completed Boston Seaport lab complex for sublease as it shrinks its real estate ...
Ginkgo Bioworks price target lowered to $6 from $7 at BTIG
BTIG analyst Mark Massaro lowered the firm’s price target on Ginkgo Bioworks (DNA) to $6 from $7 and keeps a Sell rating on the shares ...
Ginkgo cancels move to new South Boston lab, exits Cambridge office
Ginkgo Bioworks is headquartered at 27 Drydock Avenue in Boston's Seaport. Ginkgo has canceled its planned move into a ...
Le Lézard6d
Ginkgo Bioworks Reports Third Quarter 2024 Financial Results
Ginkgo Bioworks Holdings, Inc. , which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September ...